Kim Buck

Talent Acquisition

[Kim Buck @KimBuckBiotech]

Maze has launched a new resource for the APOL1 #kidneydisease community. Visit https://t.co/dKMknjDvEF to learn about kidney disease, explore Maze's HORIZON clinical trial, and share with your network. Together, we can raise awareness and support the APOL1 kidney community!

[Maze Therapeutics @MazeInBiotech]

In honor of APOL1 Awareness Day, we're proud to share a new resource for the APOL1 #kidneydisease community. This resource provides accessible, expert-informed information for individuals and families affected by APOL1 kidney disease, especially those of African ancestry, who are disproportionately impacted. Education and awareness are essential steps toward better care and earlier detection, and we hope this site helps empower the community. Learn more: https://t.co/524TAQ77vr #APOL1aware

[Maze Therapeutics @MazeInBiotech]

Today, we honor #InternationalPompeDay alongside those within the #PompeDisease community. Please join us as we celebrate this group of resilient and dedicated individuals. #TogetherWeAreStrong

[Maze Therapeutics @MazeInBiotech]

In honor of #WomensHistoryMonth, Maze's DEI council hosted a panel discussion featuring four Mazers who shared their inspiring career journeys and emphasized the significance of everyday acts of inclusion. A huge thank you to our panelists for sharing their insights!

[Maze Therapeutics @MazeInBiotech]

We are pleased to announce the initiation of our Phase 1 trial of MZE829. MZE829 is an oral, small molecule APOL1 inhibitor designed to block APOL1 pore function and ameliorate manifestations of APOL1 #kidneydisease. (1/2)

[Maze Therapeutics @MazeInBiotech]

The FTC has filed a complaint seeking to block Sanofi’s exclusive worldwide license agreement for Maze’s glycogen synthase 1 (GYS1) program, including clinical candidate MZE001. We respectfully disagree with this unprecedented decision and believe that... (1/2)

[Maze Therapeutics @MazeInBiotech]

We look forward to urgently delivering transformative precision medicine to patients. Congratulations to all of the Endpoints 11 winners and finalists! We look forward to urgently continuing our work in common diseases. (2/2)

[Maze Therapeutics @MazeInBiotech]

We're honored to be recognized as part of this year's @endpts 11 awards. Thank you to John Carroll and the Endpoints team for recognizing the incredible progress our exceptional & dedicated team has made. https://t.co/TLdGOONimB (1/2)

[Maze Therapeutics @MazeInBiotech]

Our CEO and President, R&D/CMO will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on September 26. A live webcast of the presentation will be available in the news & press section of our website. https://t.co/gkANoJX1L7

[Maze Therapeutics @MazeInBiotech]

We tied our walking shoes to support #kidneydisease patients at @nkf's Northern California Kidney Walk. Thanks to our team for their passion & for participating in this event in support of the NKF. We're committed to spreading #kidneydisease awareness both in & out of the office.

[Maze Therapeutics @MazeInBiotech]

As #PrideMonth2023 concludes this week, we share our support for the LGBTQIA+ community, hosting a firm-wide event in recognition of Pride. We celebrate everyone's individuality here at Maze and are proud to foster an inclusive culture and promote further awareness and education.

[Maze Therapeutics @MazeInBiotech]

Listen in as we present a corporate overview on Maze at the @JefferiesEvents Healthcare Conference on Thursday, June 8, 2023, at 11:30 a.m. ET. A webcast & replay of the presentation will be available on our website. https://t.co/64jy3kWYCw #JefferiesHealthcare

[Parkinson's Foundation @ParkinsonDotOrg]

Today is World Parkinson’s Day! 🌎 Every 6 minutes, someone new is diagnosed with Parkinson's disease ⏳ #Take6forPD and help us spread awareness and resources for everyone living with PD by sharing this post 🤝 https://t.co/ZbpqmdKFn0

[Maze Therapeutics @MazeInBiotech]

We're presenting encouraging new data from an exploratory cohort of our Phase 1 MZE001 trial at @MDAorg's Clinical & Scientific Conference in Dallas. Data further supports proof of mechanism for MZE001 & provides validation for our non-invasive biomarker. https://t.co/8vh9uU7Dvf

[The Nobel Prize @NobelPrize]

Marie Skłodowska Curie defended her doctoral thesis on radioactive substances at Université de la Sorbonne in Paris on 25 June 1903 – becoming the first woman in France to receive a doctoral degree.

[Fight Colorectal Cancer @FightCRC]

Throughout March, @AICAF_Org encourages Native people everywhere to get involved by getting screened, raising awareness, and showing support for #colorectalcancer survivors & caregivers by wearing blue! 💙 Learn more: https://t.co/8A0s6JZPdR

[Freenome @freenome]

We're presenting today at @WesternC4 on the subject population of our large study for #ColorectalCancer. Our tests are designed for everyone-so our studies should reflect that. #ColorectalCancerAwarenessMonth https://t.co/XaMa5220iP

[Freenome @freenome]

We were honored to respond to The @WhiteHouse’s call to action to increase access to #colorectalcancer screening with @FightCRC and other industry leaders. Learn more about the experience and what we’re doing together.

https://t.co/UzjAJZguRI

[MCU - The Direct @MCU_Direct]

Don Cheadle has confirmed that he's finished with his contractual obligations with #MarvelStudios:

“I’m done with my contracted years in the MCU, so now, it’s just like, if something sounds fun and I’m presented with it, then yeah, let’s go..." Details: https://t.co/tm9pPY3c0I

[Freenome @freenome]

Today we launch the Sanderson Study which will build the infrastructure to bridge the gap between clinical research and clinical impact, and drive tailored insights for patient care.
https://t.co/sfjgQ1jF6n